Eur Rev Med Pharmacol Sci 2021; 25 (5): 2415-2417

DOI: 10.26355/eurrev_202103_25282

Flight hormones as therapeutic target for novel Coronavirus infectious disease

S.-H. Ouyang, H. Su, J.-P. He, X.-X. Li, D.-M. Lu

Department of Anesthesiology, Chenzhou No. 1 People’s Hospital, Chenzhou, Hunan, China. ludongming1971@sina.com


Coronavirus Disease 2019 (COVID-19) pandemic has made more awful effect on wellbeing and economy worldwide on an extraordinary scale. Angiotensin I Converting Enzyme 2 (ACE2), the principal receptor of SARS-CoV2, has been found to be communicated with Dopa decarboxylase in unwinding the connection of catecholamines with COVID-19 infection. Cardiovascular (CV) sickness, diabetes, hypertension, and related conditions cause significant risks during the current situation and the affected people are under basic observation around the world. The hypertension and diabetes are related with alterations in the degrees of catecholamines associated with renal gland. The naive form of renal dopaminergic framework is related with the expanded reabsorption of sodium resulting in downregulation of the ACE2 expression. Catecholamine biosynthesis is managed by counter-controlling angiotensin type 1R (AT1R) and angiotensin type 2R (AT2R), incitement of AT2 lessens catecholamine biosynthesis by means of a diminishing in cGMP levels likewise incitement of AT1 initiate catecholamine biosynthesis. This audit sums up the conceivable contribution of catecholamines in intense COVID-19 contamination and furthermore featured possible restorative adequacy of catecholamine flagging pathways against the incessant SARS-CoV-2.

Free PDF Download

To cite this article

S.-H. Ouyang, H. Su, J.-P. He, X.-X. Li, D.-M. Lu
Flight hormones as therapeutic target for novel Coronavirus infectious disease

Eur Rev Med Pharmacol Sci
Year: 2021
Vol. 25 - N. 5
Pages: 2415-2417
DOI: 10.26355/eurrev_202103_25282